Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies

NCT02476006 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02476006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02476006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
June 23, 2015
Completion date
April 12, 2019
Enrollment
998 (actual)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia